ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™

NARecruitingINTERVENTIONAL
Enrollment

1,016

Participants

Timeline

Start Date

June 18, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

February 29, 2036

Conditions
Aortic RegurgitationAortic Valve InsufficiencyAortic Insufficiency
Interventions
DEVICE

Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System

Transcatheter Aortic Valve Replacement (TAVR) with Trilogy Device

DEVICE

SAVR

SAVR using commercially available surgical prosthetic valves.

Trial Locations (13)

10032

RECRUITING

Cumc/Nyph, New York

23507

RECRUITING

Sentara Norfolk, Norfolk

30308

RECRUITING

Emory University Hospital, Atlanta

30369

RECRUITING

Piedmont Healthcare, Atlanta

33756

RECRUITING

BayCare Health, Clearwater

45219

RECRUITING

The Christ Hospital, Cincinnati

48202

RECRUITING

Henry Ford Health, Detroit

55407

RECRUITING

Minneapolis Heart Institute Founcation, Minneapolis

77030

RECRUITING

Houston Methodist Research Institute, Houston

84111

RECRUITING

Intermountain Health, Murray

90048

RECRUITING

Cedar-Sinai Medical Center, Los Angeles

92037

RECRUITING

Scripps Health, La Jolla

94010

RECRUITING

CPMC Sutter Health, Burlingame

Sponsors
All Listed Sponsors
lead

JenaValve Technology, Inc.

INDUSTRY

NCT06608823 - ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | Biotech Hunter | Biotech Hunter